Abstract
In the majority of these reports, objective response rates of > 25% and disease control rates of > 60% have been described. Treatment with gefitinib resulted in a median time to progression of > 3 months and a median survival time of > 6 months in most studies. These 31 reports also demonstrated the efficacy of gefitinib in patients with secondary brain metastases, those with poor performance status (PS) and in patients receiving the drug as first-line treatment. Female gender, adenocarcinoma histology, non-smoking history, good PS and the presence of multiple lung metastases are associated with improved responsiveness to gefitinib. Reflecting the results of previous clinical trials, the reports indicate that gefitinib is generally well tolerated by Asian patients. The incidence of interstitial lung disease appears to be higher in Japanese than non-Japanese patients, although the reasons for this are not clear. Recent findings regarding cellular and genetic factors that may underlie the increased responsiveness to gefitinib among Asian patients are discussed.
Keywords
GefitinibMedicineInternal medicineLung cancerPlaceboOncologyClinical trialCancerEpidermal growth factor receptorPathologyAlternative medicine
Affiliated Institutions
Related Publications
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
Abstract The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the...
High Performance of <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer
<b><i>Background:</i></b> The diagnostic evaluation of patients presenting with possible lung cancer is often complex and time consuming. A rapid outpati...
Publication Info
- Year
- 2006
- Type
- review
- Volume
- 22
- Issue
- 3
- Pages
- 561-573
- Citations
- 92
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
92
OpenAlex
Cite This
Keunchil Park,
Kōichi Goto
(2006).
A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer.
Current Medical Research and Opinion
, 22
(3)
, 561-573.
https://doi.org/10.1185/030079906x89847
Identifiers
- DOI
- 10.1185/030079906x89847